Julie K. Klint

Julie K. Klint

Auto-generated profile, based on publicly available information

Julie K. Klint

H. Lundbeck A/S. Ottiliavej 9, 2500 Valby, Denmark

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Toxicon
Verified
Journal Article
Closed access
JKJulie K. Klint
Julie K. Klint
SSSebastian Senff
Sebastian Senff
DRDarshani B. Rupasinghe
Darshani B. Rupasinghe
SESing Yan Er
Sing Yan Er
Volker HerzigVolker Herzig
Volker Herzig
Glenn KingGlenn King
Glenn King

7 May 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JKJulie K Klint
Julie K Klint
SSSebastian Senff
Sebastian Senff
NSNatalie J Saez
Natalie J Saez
RSRadha Seshadri
Radha Seshadri
HLHo Yee Lau
Ho Yee Lau
Glenn KingGlenn King
Glenn King
Disulfide-rich peptides are the dominant component of most animal venoms. These peptides have received much attention as leads for the development of novel therapeutic agents and bioinsecticides because they target a wide range of neuronal receptors and ion channels with a high degree of potency and selectivity. In addition, their rigid disulfide framework makes them particularly well suited for addressing the crucial issue of in vivo stability. Structural and functional characterization of these peptides necessitates the development of a robust, reliable expression system that maintains their native disulfide framework. The bacterium Escherichia coli has long been used for economical production of recombinant proteins. However, the expression of functional disulfide-rich proteins in the reducing environment of the E. coli cytoplasm presents a significant challenge. Thus, we present here an optimised protocol for the expression of disulfide-rich venom peptides in the periplasm of E. coli , which is where the endogenous machinery for production of disulfide-bonds is located. The parameters that have been investigated include choice of media, induction conditions, lysis methods, methods of fusion protein and peptide purification, and sample preparation for NMR studies. After each section a recommendation is made for conditions to use. We demonstrate the use of this method for the production of venom peptides ranging in size from 2 to 8 kDa and containing 2–6 disulfide bonds.

30 September 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
SYShilong Yang
Shilong Yang
YXYao Xiao
Yao Xiao
DKDi Kang
Di Kang
LJLiu Jie
Liu Jie
YLYuan Li
Yuan Li
Glenn KingGlenn King
Glenn King
Significance: The economic burden of chronic pain in the United States is currently ∼$600 billion per annum, which exceeds the combined annual cost of cancer, heart disease, and diabetes. Few drugs are available for treating chronic pain, and many have limited efficacy and dose-limiting side-effects. Humans with inheritable loss-of-function mutations in the voltage-gated sodium channel Na V 1.7 are indifferent to all types of pain, and therefore drugs that block this channel should be useful analgesics for treating many pain conditions. Herein we describe Ssm6a, a peptide from centipede venom that potently and selectively blocks the human Na V 1.7 channel. Ssm6a proved to be more analgesic than morphine in rodent pain models and did not cause any side-effects.

13 July 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
MBMathieu Botte
Mathieu Botte
SHSophie Huber
Sophie Huber
DBDenis Bucher
Denis Bucher
JKJulie K. Klint
Julie K. Klint
DRDavid Rodríguez
David Rodríguez
WRWassim Abdul Rahman
Wassim Abdul Rahman
Kv3 ion-channels constitute a class of functionally distinct voltage gated ion channels characterized by their ability to fire at a high frequency. Several disease relevant mutants, together with biological data, suggest the importance of this class of ion channels as drug targets for CNS disorders, and several drug discovery efforts have been reported. Despite the increasing interest for this class of ion channels, no structure of a Kv3 channel has been reported yet. We have determined the cryo-EM structure of Kv3.1 at 2.6 Å resolution using full length wild type protein. When compared to known structures for potassium channels from other classes, a novel domain organization is observed with the cytoplasmic T1 domain, containing a well resolved Zinc site and displaying a rotation by 35°. This suggests a distinct cytoplasmic regulation mechanism for the Kv3.1 channel. A high resolution structure was obtained for Kv3.1 in complex with a novel positive modulator Lu AG00563. The structure reveals a novel ligand binding site for the Kv class of ion channels located between the voltage sensory domain and the channel pore, a region which constitutes a hotspot for disease causing mutations. The discovery of a novel binding site for a positive modulator of a voltage gated potassium channel could shed light on the mechanism of action for these small molecule potentiators. This finding could enable structure-based drug design on these targets with high therapeutic potential for the treatment of multiple CNS disorders.

1 August 2012 in Toxicon
Verified
Journal Article
Closed access
JKJulie Klint
Julie Klint
RARaveendra Anangi
Raveendra Anangi
MMMehdi Mobli
Mehdi Mobli
OKOliver Knapp
Oliver Knapp
DADavid J. Adams
David J. Adams
Glenn KingGlenn King
Glenn King